{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:25:03Z","timestamp":1775060703193,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1208\/s12248-019-0357-3","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T16:02:50Z","timestamp":1563465770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats"],"prefix":"10.1208","volume":"21","author":[{"given":"Tianjing","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengbi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"357_CR1","first-page":"1","volume":"2013","author":"SYK Fong","year":"2013","unstructured":"Fong SYK, Gao Q, Zuo Z. Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review. Evid Based Complement Alternat Med. 2013;2013:1\u201315.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"357_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00007691-199802000-00010","volume":"20","author":"M Bialer","year":"1998","unstructured":"Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit. 1998;20(1):56\u20139.","journal-title":"Ther Drug Monit"},{"issue":"Suppl 3","key":"357_CR3","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1111\/j.1528-1157.1987.tb05780.x","volume":"28","author":"JM Pellock","year":"1987","unstructured":"Pellock JM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28(Suppl 3):S64\u201370.","journal-title":"Epilepsia."},{"issue":"7","key":"357_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239\u201376.","journal-title":"Epilepsia."},{"issue":"4","key":"357_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/cpt1975174433","volume":"17","author":"WD Hooper","year":"1975","unstructured":"Hooper WD, Dubetz DK, Bochner F, Cotter LM, Smith GA, Eadie MJ, et al. Plasma protein binding of carbamazepine. Clin Pharmacol Ther. 1975;17(4):433\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"357_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0031-6989(74)80028-7","volume":"6","author":"E Di Salle","year":"1974","unstructured":"Di Salle E, Pacifici GM, Morselli PL. Studies on plasma protein binding of carbamazepine. Pharmacol Res Commun. 1974;6(2):193\u2013202. \n                    https:\/\/doi.org\/10.1016\/S0031-6989(74)80028-7\n                    \n                  .","journal-title":"Pharmacol Res Commun"},{"issue":"369707","key":"357_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/369707","volume":"2015","author":"JL Russell","year":"2015","unstructured":"Russell JL, Spiller HA, Baker DD. Markedly elevated carbamazepine-10,11-epoxide\/carbamazepine ratio in a fatal carbamazepine ingestion. Case Rep Med. 2015;2015(369707):1\u20134. \n                    https:\/\/doi.org\/10.1155\/2015\/369707\n                    \n                  .","journal-title":"Case Rep Med"},{"issue":"8","key":"357_CR8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/archneur.1990.00530080072013","volume":"47","author":"T Tomson","year":"1990","unstructured":"Tomson T, Almkvist O, Nilsson BY, Svensson JO, Bertilsson L. Carbamazepine-10,11-epoxide in epilepsy. A pilot study. Arch Neurol. 1990;47(8):888\u201392.","journal-title":"Arch Neurol"},{"issue":"11","key":"357_CR9","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","volume":"47","author":"BM Kerr","year":"1994","unstructured":"Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47(11):1969\u201379.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"357_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrd753","volume":"1","author":"TM Willson","year":"2002","unstructured":"Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002;1(4):259\u201366. \n                    https:\/\/doi.org\/10.1038\/nrd753\n                    \n                  .","journal-title":"Nat Rev Drug Discov"},{"key":"357_CR11","unstructured":"Daniels R. Delmar's manual of laboratory and diagnostic tests: Cengage Learning; 2009."},{"issue":"4","key":"357_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1055\/s-0031-1279730","volume":"44","author":"A Sanchez-Romero","year":"2011","unstructured":"Sanchez-Romero A, Mayordomo-Aranda A, Garcia-Delgado R, Duran-Quintana JA. Probable interaction between trazodone and carbamazepine. Pharmacopsychiatry. 2011;44(4):158\u20139. \n                    https:\/\/doi.org\/10.1055\/s-0031-1279730\n                    \n                  .","journal-title":"Pharmacopsychiatry."},{"issue":"8483","key":"357_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(86)91099-8","volume":"1","author":"GJ Macphee","year":"1986","unstructured":"Macphee GJ, McInnes GT, Thompson GG, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet. 1986;1(8483):700\u20133.","journal-title":"Lancet"},{"issue":"2","key":"357_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00210-017-1439-3","volume":"391","author":"SK Bedada","year":"2018","unstructured":"Bedada SK, Neerati P. Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. Naunyn Schmiedeberg's Arch Pharmacol. 2018;391(2):115\u201321. \n                    https:\/\/doi.org\/10.1007\/s00210-017-1439-3\n                    \n                  .","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"10","key":"357_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/00498254.2016.1244368","volume":"47","author":"SK Bedada","year":"2017","unstructured":"Bedada SK, Boga PK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879\u201384. \n                    https:\/\/doi.org\/10.1080\/00498254.2016.1244368\n                    \n                  .","journal-title":"Xenobiotica."},{"issue":"5","key":"357_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/ptr.5302","volume":"29","author":"SK Bedada","year":"2015","unstructured":"Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. Phytother Res. 2015;29(5):701\u20136. \n                    https:\/\/doi.org\/10.1002\/ptr.5302\n                    \n                  .","journal-title":"Phytother Res"},{"issue":"3","key":"357_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/s0009-9236(98)90177-1","volume":"64","author":"SK Garg","year":"1998","unstructured":"Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther. 1998;64(3):286\u20138. \n                    https:\/\/doi.org\/10.1016\/s0009-9236(98)90177-1\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"357_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1600-0404.1973.tb01327.x","volume":"49","author":"J Christiansen","year":"1973","unstructured":"Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand. 1973;49(4):543\u20136.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"357_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1528-1157.1991.tb05624.x","volume":"32","author":"F Albani","year":"1991","unstructured":"Albani F, Theodore WH, Washington P, Devinsky O, Bromfield E, Porter RJ, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia. 1991;32(1):130\u20132.","journal-title":"Epilepsia."},{"issue":"10","key":"357_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jpsychires.2006.08.002","volume":"41","author":"Z Zhang","year":"2007","unstructured":"Zhang Z, Kang WH, Li Q, Tan Q. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies. J Psychiatr Res. 2007;41(10):828\u201336. \n                    https:\/\/doi.org\/10.1016\/j.jpsychires.2006.08.002\n                    \n                  .","journal-title":"J Psychiatr Res"},{"issue":"4","key":"357_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/clpt.1988.45","volume":"43","author":"C Neef","year":"1988","unstructured":"Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther. 1988;43(4):372\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"357_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3109\/03639049509070866","volume":"21","author":"MA Etman","year":"1995","unstructured":"Etman MA. Effect of a bulk forming laxative on the bioavailability of carbamazepine in man. Drug Dev Ind Pharm. 1995;21(16):1901\u20136. \n                    https:\/\/doi.org\/10.3109\/03639049509070866\n                    \n                  .","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"357_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00007691-198206000-00004","volume":"4","author":"GF Mattson","year":"1982","unstructured":"Mattson GF, Mattson RH, Cramer JA. Interaction between valproic acid and carbamazepine: an in vitro study of protein binding. Ther Drug Monit. 1982;4(2):181\u20134.","journal-title":"Ther Drug Monit"},{"key":"357_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1079\/9781845934057.0021","volume-title":"Chemistry of spices","author":"TJ Zachariah","year":"2008","unstructured":"Zachariah TJ, Parthasarathy VA. Black pepper. In: Parthasarathy VA, Chempakam B, Zachariah TJ, editors. Chemistry of spices. UK: CABI; 2008. p. 21\u201340."},{"key":"357_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.pbb.2013.01.002","volume":"104","author":"GM da Cruz","year":"2013","unstructured":"da Cruz GM, Felipe CF, Scorza FA, da Costa MA, Tavares AF, Menezes ML, et al. Piperine decreases pilocarpine-induced convulsions by GABAergic mechanisms. Pharmacol Biochem Behav. 2013;104:144\u201353. \n                    https:\/\/doi.org\/10.1016\/j.pbb.2013.01.002\n                    \n                  .","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20133","key":"357_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejphar.2013.07.041","volume":"714","author":"CY Chen","year":"2013","unstructured":"Chen CY, Li W, Qu KP, Chen CR. Piperine exerts anti-seizure effects via the TRPV1 receptor in mice. Eur J Pharmacol. 2013;714(1\u20133):288\u201394. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2013.07.041\n                    \n                  .","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"357_CR27","first-page":"557","volume":"46","author":"R D'Hooge","year":"1996","unstructured":"D'Hooge R, Pei YQ, Raes A, Lebrun P, van Bogaert PP, de Deyn PP. Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. Arzneimittelforschung. 1996;46(6):557\u201360.","journal-title":"Arzneimittelforschung."},{"key":"357_CR28","unstructured":"Hospital P. Initial experience of treating epilepsy by piperine. Acad J Peking Univ. 1974;(04):214\u201322."},{"issue":"2","key":"357_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1124\/jpet.102.034728","volume":"302","author":"RK Bhardwaj","year":"2002","unstructured":"Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;302(2):645\u201350. \n                    https:\/\/doi.org\/10.1124\/jpet.102.034728\n                    \n                  .","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"357_CR30","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1089\/jmf.2010.1065","volume":"13","author":"MH Mehmood","year":"2010","unstructured":"Mehmood MH, Gilani AH. Pharmacological basis for the medicinal use of black pepper and piperine in gastrointestinal disorders. J Med Food. 2010;13(5):1086\u201396. \n                    https:\/\/doi.org\/10.1089\/jmf.2010.1065\n                    \n                  .","journal-title":"J Med Food"},{"issue":"1","key":"357_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0014-2999(90)94061-2","volume":"186","author":"M Takaki","year":"1990","unstructured":"Takaki M, Jin JG, Lu YF, Nakayama S. Effects of piperine on the motility of the isolated guinea-pig ileum: comparison with capsaicin. Eur J Pharmacol. 1990;186(1):71\u20137.","journal-title":"Eur J Pharmacol"},{"key":"357_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.lfs.2018.12.060","volume":"218","author":"T Ren","year":"2019","unstructured":"Ren T, Yang M, Xiao M, Zhu J, Xie W, Zuo Z. Time-dependent inhibition of carbamazepine metabolism by piperine in anti-epileptic treatment. Life Sci. 2019;218:314\u201323. \n                    https:\/\/doi.org\/10.1016\/j.lfs.2018.12.060\n                    \n                  .","journal-title":"Life Sci"},{"issue":"9","key":"357_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/ptr.2676","volume":"23","author":"S Pattanaik","year":"2009","unstructured":"Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother Res. 2009;23(9):1281\u20136. \n                    https:\/\/doi.org\/10.1002\/ptr.2676\n                    \n                  .","journal-title":"Phytother Res"},{"issue":"1","key":"357_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1055\/s-0042-118173","volume":"67","author":"SK Bedada","year":"2017","unstructured":"Bedada SK, Appani R, Boga PK. Effect of piperine on the metabolism and pharmacokinetics of carbamazepine in healthy volunteers. Drug research. 2017;67(1):46\u201351. \n                    https:\/\/doi.org\/10.1055\/s-0042-118173\n                    \n                  .","journal-title":"Drug research"},{"key":"357_CR35","first-page":"21","volume-title":"The blood brain barrier (BBB)","author":"M Hammarlund-Udenaes","year":"2014","unstructured":"Hammarlund-Udenaes M. In vivo approaches to assessing the blood\u2013brain barrier. In: Fricker G, Ott M, Mahringer A, editors. The blood brain barrier (BBB). Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 21\u201348."},{"key":"357_CR36","volume":"24","author":"C Liu","year":"2016","unstructured":"Liu C, Zhou J, Zhang Y, Zhu T, Wang R, Li C. Validation of the zebrafish pentylenetetrazol seizure model: behavior assay for assessing anti-epileptic drug efficacy. Biochem Anal Biochem. 2016;24:1000270.","journal-title":"Biochem Anal Biochem"},{"issue":"6","key":"357_CR37","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1208\/s12248-014-9664-x","volume":"16","author":"Q Gao","year":"2014","unstructured":"Gao Q, Zhang Y, Wo S, Zuo Z. Elucidation of arctigenin pharmacokinetics after intravenous and oral administrations in rats: integration of in vitro and in vivo findings via semi-mechanistic pharmacokinetic modeling. AAPS J. 2014;16(6):1321\u201333.","journal-title":"AAPS J"},{"issue":"3","key":"357_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0014-2999(99)00083-7","volume":"369","author":"JF Graumlich","year":"1999","unstructured":"Graumlich JF, McLaughlin RG, Birkhahn D, Shah N, Burk A, Jobe PC, et al. Carbamazepine pharmacokinetics\u2013pharmacodynamics in genetically epilepsy-prone rats. Eur J Pharmacol. 1999;369(3):305\u201311.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"357_CR39","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/00498254.2017.1405293","volume":"48","author":"T Ren","year":"2018","unstructured":"Ren T, Wang Q, Li C, Yang M, Zuo Z. Efficient brain uptake of piperine and its pharmacokinetics characterization after oral administration. Xenobiotica. 2018;48(12):1249\u201357. \n                    https:\/\/doi.org\/10.1080\/00498254.2017.1405293\n                    \n                  .","journal-title":"Xenobiotica."},{"issue":"1","key":"357_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jala.2010.06.002","volume":"16","author":"S van Liempd","year":"2011","unstructured":"van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R. Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. J Lab Autom. 2011;16(1):56\u201367. \n                    https:\/\/doi.org\/10.1016\/j.jala.2010.06.002\n                    \n                  .","journal-title":"J Lab Autom"},{"key":"357_CR41","doi-asserted-by":"crossref","unstructured":"Tassalit D, Chekir N, Benhabiles O, Mouzaoui O, Mahidine S, Merzouk NK, et al. Effect and interaction study of acetamiprid photodegradation using experimental design. Water Sci Technol. 2016:wst2016382.","DOI":"10.2166\/wst.2016.382"},{"issue":"8","key":"357_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/bdd.1908","volume":"35","author":"K Ball","year":"2014","unstructured":"Ball K, Bouzom F, Scherrmann J-M, Walther B, Decl\u00e8ves X. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human. Biopharm Drug Dispos. 2014;35(8):485\u201399. \n                    https:\/\/doi.org\/10.1002\/bdd.1908\n                    \n                  .","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"357_CR43","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharma Res. 1993;10(7):1093\u20135.","journal-title":"Pharma Res."},{"issue":"2","key":"357_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jneumeth.2008.04.019","volume":"172","author":"G Curia","year":"2008","unstructured":"Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008;172(2):143\u201357.","journal-title":"J Neurosci Methods"},{"issue":"3","key":"357_CR45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","volume":"32","author":"RJ Racine","year":"1972","unstructured":"Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32(3):281\u201394.","journal-title":"Electroencephalogr Clin Neurophysiol"},{"issue":"5","key":"357_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1023\/A:1015872901523","volume":"7","author":"RP Remmel","year":"1990","unstructured":"Remmel RP, Sinz MW, Cloyd JC. Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide. Pharma Res. 1990;7(5):513\u20137.","journal-title":"Pharma Res"},{"issue":"5","key":"357_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/BF01059329","volume":"13","author":"SL Chang","year":"1985","unstructured":"Chang SL, Levy RH. Inhibition of epoxidation of carbamazepine by valproic acid in the isolated perfused rat liver. J Pharmacokinet Pharmacodyn. 1985;13(5):453\u201366.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"357_CR48","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1124\/jpet.102.047530","volume":"305","author":"AC Egnell","year":"2003","unstructured":"Egnell AC, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther. 2003;305(3):1251\u201362. \n                    https:\/\/doi.org\/10.1124\/jpet.102.047530\n                    \n                  .","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"357_CR49","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/BF00168955","volume":"345","author":"W Daniel","year":"1992","unstructured":"Daniel W, Janczar L, Danek L, Legrum W, Netter KJ. Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats. Naunyn Schmiedeberg's Arch Pharmacol. 1992;345(5):598\u2013605.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"357_CR50","unstructured":"Production, Supply and Distribution Database. [Internet]. USDA Foreign Agricultural Service. 2018. Available from: \n                    http:\/\/apps.fas.usda.gov\/psdonline\/app\/index.html\n                    \n                  -\/app\/home."},{"issue":"1","key":"357_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/NT.0b013e3181cb4539","volume":"45","author":"K Singletary","year":"2010","unstructured":"Singletary K. Black pepper: overview of health benefits. Nutr Today. 2010;45(1):43\u20137.","journal-title":"Nutr Today"},{"key":"357_CR52","unstructured":"FDA. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In: Services UDoHaH, editor 2005. p. 1\u201327."},{"issue":"3","key":"357_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0920-1211(96)00011-3","volume":"24","author":"I Bernus","year":"1996","unstructured":"Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res. 1996;24(3):163\u201372. \n                    https:\/\/doi.org\/10.1016\/0920-1211(96)00011-3\n                    \n                  .","journal-title":"Epilepsy Res"},{"issue":"6","key":"357_CR54","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/j.1552-4604.1986.tb03558.x","volume":"26","author":"L Bertilsson","year":"1986","unstructured":"Bertilsson L, Tomson T, Tyhring G. Pharmacokinetics: time-dependent changes\u2014autoinduction of carbamazepine epoxidation. J Clin Pharmacol. 1986;26(6):459\u201362.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"357_CR55","first-page":"619","volume":"24","author":"SK Panesar","year":"1996","unstructured":"Panesar SK, Bandiera SM, Abbott FS. Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat. Drug Metab Dispos. 1996;24(6):619\u201327.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"357_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/S1461145701002747","volume":"5","author":"H Yamashita","year":"2002","unstructured":"Yamashita H, Kazawa T, Minatogawa Y, Ebisawa T, Yamauchi T. Time-course of hepatic cytochrome P450 subfamily induction by chronic carbamazepine treatment in rats. Int J Neuropsychopharmacol. 2002;5(1):47\u201352.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"357_CR57","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/food.200390091","volume":"47","author":"RR Ramakrishna","year":"2003","unstructured":"Ramakrishna RR, Platel K, Srinivasan K. In vitro influence of spices and spice-active principles on digestive enzymes of rat pancreas and small intestine. Nahrung. 2003;47(6):408\u201312. \n                    https:\/\/doi.org\/10.1002\/food.200390091\n                    \n                  .","journal-title":"Nahrung."},{"issue":"3","key":"357_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00271363","volume":"44","author":"R Miller","year":"1993","unstructured":"Miller R, Ludden TM. Bioavailability of controlled release carbamazepine estimated by mixed effect modelling. Eur J Clin Pharmacol. 1993;44(3):231\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"357_CR59","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/ptr.5929","volume":"31","author":"RK Dubey","year":"2017","unstructured":"Dubey RK, Leeners B, Imthurn B, Merki-Feld GS, Rosselli M. Piperine decreases binding of drugs to human plasma and increases uptake by brain microvascular endothelial cells. Phytother Res. 2017;31(12):1868\u201374. \n                    https:\/\/doi.org\/10.1002\/ptr.5929\n                    \n                  .","journal-title":"Phytother Res"},{"issue":"5","key":"357_CR60","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1208\/s12248-017-0108-2","volume":"19","author":"M Hammarlund-Udenaes","year":"2017","unstructured":"Hammarlund-Udenaes M. Microdialysis as an important technique in systems pharmacology\u2014a historical and methodological review. AAPS J. 2017;19(5):1294\u2013303. \n                    https:\/\/doi.org\/10.1208\/s12248-017-0108-2\n                    \n                  .","journal-title":"AAPS J"},{"issue":"3","key":"357_CR61","first-page":"1217","volume":"272","author":"K Van Belle","year":"1995","unstructured":"Van Belle K, Sarre S, Ebinger G, Michotte Y. Brain, liver and blood distribution kinetics of carbamazepine and its metabolic interaction with clomipramine in rats: a quantitative microdialysis study. J Pharmacol Exp Ther. 1995;272(3):1217\u201322.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"357_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1745-7254.2006.00246.x","volume":"27","author":"J Sun","year":"2006","unstructured":"Sun J, Xie L, Liu X. Transport of carbamazepine and drug interactions at blood-brain barrier. Acta Pharmacol Sin. 2006;27(2):249\u201353. \n                    https:\/\/doi.org\/10.1111\/j.1745-7254.2006.00246.x\n                    \n                  .","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"357_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064854","volume":"8","author":"D Dickens","year":"2013","unstructured":"Dickens D, Yusof SR, Abbott NJ, Weksler B, Romero IA, Couraud PO, et al. A multi-system approach assessing the interaction of anticonvulsants with P-gp. PLoS One. 2013;8(5):e64854. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0064854\n                    \n                  .","journal-title":"PLoS One"},{"issue":"16","key":"357_CR64","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1097\/00001756-200111160-00037","volume":"12","author":"H Potschka","year":"2001","unstructured":"Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport. 2001;12(16):3557\u201360.","journal-title":"Neuroreport."},{"key":"357_CR65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.phymed.2018.09.217","volume":"54","author":"X Bi","year":"2019","unstructured":"Bi X, Yuan Z, Qu B, Zhou H, Liu Z, Xie Y. Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2. Phytomedicine. 2019;54:98\u2013108. \n                    https:\/\/doi.org\/10.1016\/j.phymed.2018.09.217\n                    \n                  .","journal-title":"Phytomedicine."},{"issue":"7","key":"357_CR66","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5414\/CP201517","volume":"49","author":"JR Milovanovic","year":"2011","unstructured":"Milovanovic JR, Jankovic SM. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis. Int J Clin Pharm Ther. 2011;49(7):428\u201336.","journal-title":"Int J Clin Pharm Ther"},{"key":"357_CR67","first-page":"271","volume-title":"Drug Delivery to the Brain","author":"Irena Loryan","year":"2013","unstructured":"Loryan I, Hammarlund-Udenaes M. Drug discovery methods for studying brain drug delivery and distribution. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG, editors. Drug delivery to the brain: physiological concepts, methodologies and approaches. New York, NY: Springer New York; 2014. p. 271\u2013316."},{"issue":"3","key":"357_CR68","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1124\/dmd.110.035998","volume":"39","author":"M Friden","year":"2011","unstructured":"Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39(3):353\u201362. \n                    https:\/\/doi.org\/10.1124\/dmd.110.035998\n                    \n                  .","journal-title":"Drug Metab Dispos"},{"key":"357_CR69","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/NDT.S50371","volume":"10","author":"L Kandratavicius","year":"2014","unstructured":"Kandratavicius L, Balista PA, Lopes-Aguiar C, Ruggiero RN, Umeoka EH, Garcia-Cairasco N, et al. Animal models of epilepsy: use and limitations. Neuropsychiatr Dis Treat. 2014;10:1693\u2013705. \n                    https:\/\/doi.org\/10.2147\/NDT.S50371\n                    \n                  .","journal-title":"Neuropsychiatr Dis Treat"},{"key":"357_CR70","doi-asserted-by":"crossref","unstructured":"Post RM, Uhde TW, Ballenger JC, Bunney WE. Carbamazepine, temporal lobe epilepsy, and manic-depressive illness. Temporal lobe epilepsy, mania and schizophrenia and the limbic system, vol. 8: Karger Publishers; 1982. p. 117\u201356.","DOI":"10.1159\/000406761"},{"key":"357_CR71","doi-asserted-by":"crossref","unstructured":"Raol YH, Brooks Kayal AR. Experimental models of seizures and epilepsies. Prog Mol Biol Transl Sci 105: Elsevier; 2012. p. 57\u201382.","DOI":"10.1016\/B978-0-12-394596-9.00003-2"},{"issue":"5","key":"357_CR72","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","volume":"20","author":"W Loscher","year":"2011","unstructured":"Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20(5):359\u201368. \n                    https:\/\/doi.org\/10.1016\/j.seizure.2011.01.003\n                    \n                  .","journal-title":"Seizure."},{"key":"357_CR73","volume":"136","author":"T Shimada","year":"2018","unstructured":"Shimada T, Yamagata K. Pentylenetetrazole-induced kindling mouse model. J Vis Exp. 2018;136:e56573.","journal-title":"J Vis Exp"},{"key":"357_CR74","doi-asserted-by":"crossref","unstructured":"Copmans D, Siekierska A, de Witte PA. Zebrafish models of epilepsy and epileptic seizures. In: Models of seizures and epilepsy: Elsevier; 2017. p. 369\u201384.","DOI":"10.1016\/B978-0-12-804066-9.00026-2"},{"issue":"10","key":"357_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043850","volume":"7","author":"J Maes","year":"2012","unstructured":"Maes J, Verlooy L, Buenafe OE, De Witte PA, Esguerra CV, Crawford AD. Evaluation of 14 organic solvents and carriers for screening applications in zebrafish embryos and larvae. PLoS One. 2012;7(10):e43850.","journal-title":"PLoS One"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0357-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-019-0357-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0357-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:05:58Z","timestamp":1594940758000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-019-0357-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1208\/s12248-019-0357-3","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"90"}}